IMMUNOBIOLOGY RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
نویسندگان
چکیده
1Department of Internal Medicine III, University of Ulm, Ulm, Germany; 2Institute for Transfusion Medicine, University of Ulm and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm Gemeinnützige gGmbH, Ulm, Germany; 3Lublin Medical University, Department of Clinical Immunology, Lublin, Poland; 4Ludwig Institute for Cancer Research (LICR) New York Branch, Memorial Sloan-Kettering Cancer Center, New York, NY; 5Division of Clinical Onco-Immunology, LICR, Hôpital Orthopédique, Lausanne, Switzerland; 6LICR, Lausanne Branch, University of Lausanne, Epalinges, Switzerland; and 7Mie University Medical School, Tsu, Japan
منابع مشابه
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.
The receptor for hyaluronic acid-mediated motility (RHAMM) is an antigen eliciting both humoral and cellular immune responses in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and multiple myeloma (MM). We initiated a phase 1 clinical trial vaccinating 10 patients with R3 (ILSLELMKL), a highly immunogenic CD8(+) T-cell epitope peptide derived from RHAMM. In 7 of 10 ...
متن کاملHigh-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.
BACKGROUND Recently, we demonstrated immunological and clinical responses to a RHAMM-R3 peptide vaccine in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. To improve the outcome of the vaccine, a second cohort was vaccinated with a higher dose of 1,000 microg peptide. DESIGN AND METHODS Nine patients received four vaccinations subcutaneously at a biweekly ...
متن کاملHigh dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM)
Background: Recently, we demonstrated immunological and clinical responses to a RHAMM-R3 peptide vaccine in patients with acute myeloid leukemia, myelodysplastic syndrome (MDS) and multiple myeloma (MM). To improve the outcome of the vaccine, a second cohort was vaccinated with a higher dose of 1,000μg peptide. Design and Methods: Nine patients received four vaccinations subcutaneously at a biw...
متن کاملRHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits im
Michael Schmitt, Anita Schmitt, Markus T. Rojewski, Jinfei Chen, Krzysztof Giannopoulos, Fei Fei, Yingzhe Yu, Marlies Götz, Marta Heyduk, Gerd Ritter, Daniel E. Speiser, Sacha Gnjatic, Philippe Guillaume, Mark Ringhoffer, Richard F. Schlenk, Peter Liebisch, Donald Bunjes, Hiroshi Shiku, Hartmut Dohner, and Jochen Greiner Department of Internal Medicine III, University of Ulm, Robert-Koch-Str. 8...
متن کاملImmune Responses to RHAMM in Patients with Acute Myeloid Leukemia after Chemotherapy and Allogeneic Stem Cell Transplantation
Leukemic blasts overexpress immunogenic antigens, so-called leukemia-associated antigens like the receptor for hyaluronan acid-mediated motility (RHAMM). Persistent RHAMM expression and decreasing CD8+ T-cell responses to RHAMM in the framework of allogeneic stem cell transplantation or chemotherapy alone might indicate the immune escape of leukemia cells. In the present study, we analyzed the ...
متن کامل